Pfizer confirms COVID pill’s results, potency versus omicron
The Hindu
Pfizer is also studying its pill in lower-risk adults — including a subset who are vaccinated — but reported mixed data for that group on Tuesday.
Pfizer said on Tuesday that its experimental COVID-19 pill appears effective against the omicron variant.
The company also said full results of its 2,250-person study confirmed the pill’s promising early results against the virus: The drug reduced combined hospitalizations and deaths by about 89% among high-risk adults when taken shortly after initial COVID-19 symptoms.
Separate laboratory testing shows the drug retains its potency against the omicron variant, the company announced, as many experts had predicted. Pfizer tested the antiviral drug against a man-made version of a key protein that omicron uses to reproduce itself.

The draft policy for “Responsible Digital Use Among Students”, released on Monday by the Department of Health and Family Welfare, has recommended that parents set structured routines with clear screen-time rules and prioritise privacy, safety, and open conversation with children on digital well-being.












